Skip to main content


Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits

Fig. 3

Melatonin increased apoptosis induced by vemurafenib via the cytochrome c/caspase signaling pathway. Human melanoma cells were treated with vemurafenib (VE) (2.5 μM) and melatonin (MT) (1.0 mM) for 24 h. (a). The apoptosis was then determined by a FACS analysis. (b). Acridine orange/ethidium bromide fluorescence staining was performed in melanoma cells. (c). The release of cytochrome c (cyto-c) was monitored by immunofluorescence imaging analysis from the inter-mitochondrial space into the cytosol. (d). The levels of the Bcl-2, cleaved, caspase-3, 9 and PARP proteins were analyzed by Western blotting. The apoptosis are represented by relative percentages of apoptotic cells versus that in DMSO-treated cells

Back to article page